More evidence is needed on the additional efficacy of vedolizumab as a first-line biologic therapy for inflammatory bowel disease

被引：1
|
作者：
Kakiuchi, Toshihiko [1 ]
Yoshiura, Masato [1 ]
机构：
[1] Saga Univ, Fac Med, Dept Pediat, 5-1-1 Nabeshima, Saga 8498501, Japan
来源：
DIGESTIVE AND LIVER DISEASE | 2023年 / 55卷 / 02期
关键词：
ULCERATIVE-COLITIS; REMISSION;
D O I：
10.1016/j.dld.2022.11.004
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：298 / 299
页数：2
相关论文
共 50 条
  • [21] First or Second Biologic in Inflammatory Bowel Disease Combination Therapy or Monotherapy?
    Aoun, Roni
    Jabak, Suha
    Mourad, Fadi H.
    Francis, Fadi F.
    Regueiro, Miguel
    Hashash, Jana G.
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2021, 55 (09) : 740 - 746
  • [22] Safety and Efficacy of Biologic Therapies (Ustekinumab and Vedolizumab) in the Treatment of Inflammatory Bowel Disease (IBD): A Systematic Review
    Ashraf, Hafsa
    Bodapati, Adiprasad
    Hanif, Ayesha
    Okafor, Donatus K.
    Katyal, Gitika
    Kaur, Gursharan
    Khan, Safeera
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (11)
  • [23] Azathioprine with Allopurinol Is a Promising First-Line Therapy for Inflammatory Bowel Diseases
    van Liere, Elsa L. S. A.
    Bayoumy, Ahmed B.
    Mulder, Chris J. J.
    Warner, Ben
    Hayee, Bu
    Mateen, Bilal A.
    Nolan, Jonathan D.
    de Boer, Nanne K. H.
    Anderson, Simon H. C.
    Ansari, Azhar R.
    DIGESTIVE DISEASES AND SCIENCES, 2022, 67 (08) : 4008 - 4019
  • [24] Azathioprine with Allopurinol Is a Promising First-Line Therapy for Inflammatory Bowel Diseases
    Elsa L. S. A. van Liere
    Ahmed B. Bayoumy
    Chris J. J. Mulder
    Ben Warner
    Bu Hayee
    Bilal A. Mateen
    Jonathan D. Nolan
    Nanne K. H. de Boer
    Simon H. C. Anderson
    Azhar R. Ansari
    Digestive Diseases and Sciences, 2022, 67 : 4008 - 4019
  • [25] Efficacy of Vedolizumab as Induction Therapy for Inflammatory Bowel Disease in a 'real-life' Study
    Trefois, Quentin
    Descamps, Olivier
    Coche, Jean-Charles
    Schapira, Michael
    ACTA CLINICA BELGICA, 2016, 71 : 7 - 7
  • [26] Vedolizumab Therapy in Severe Pediatric Inflammatory Bowel Disease
    Conrad, Maire A.
    Stein, Ronen E.
    Maxwell, Elizabeth C.
    Albenberg, Lindsey
    Baldassano, Robert N.
    Dawany, Noor
    Grossman, Andrew B.
    Mamula, Petar
    Piccoli, David A.
    Kelsen, Judith R.
    INFLAMMATORY BOWEL DISEASES, 2016, 22 (10) : 2425 - 2431
  • [27] Comparative Outcomes of Adalimumab and Infliximab Dose Escalation in Inflammatory Bowel Disease Patients Failing First-Line Biologic Treatment
    Atay, Ali
    Cagir, Yavuz
    Ergul, Mucahit
    Ozturk, Oguz
    Durak, Muhammed Bahaddin
    Yuksel, Ilhami
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (04)
  • [28] Comparative outcomes of Adalimumab and Infliximab dose escalation in Inflammatory Bowel Disease patients failing first-line biologic treatment
    Atay, A.
    Cagir, Y.
    Ergul, M.
    Ozturk, O.
    Durak, M. B.
    Yuksel, I
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1775 - i1775
  • [29] Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same?
    Raine, Tim
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2014, 2 (06) : 551 - 551
  • [30] Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same?
    Raine, Tim
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2014, 2 (05) : 333 - 551
12345